{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:15:06Z","timestamp":1789823706141,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","award":["2400-13"],"award-info":[{"award-number":["2400-13"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gatorade Trust"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.leukres.2015.05.015","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T14:31:31Z","timestamp":1436020291000},"page":"984-989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition"],"prefix":"10.1016","volume":"39","author":[{"given":"Leylah","family":"Drusbosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Meacham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-6863","authenticated-orcid":false,"given":"Christopher R.","family":"Cogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.leukres.2015.05.015_bib0190","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2015.05.015_bib0195","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.2009.07919.x","article-title":"Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia","volume":"148","author":"Chauncey","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2015.05.015_bib0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/10428194.2014.918970","article-title":"Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory\/relapsed acute leukemia or high-risk myelodysplastic syndrome","volume":"56","author":"Roboz","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"7483","key":"10.1016\/j.leukres.2015.05.015_bib0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2015.05.015_bib0215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.stem.2010.02.001","article-title":"Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells","volume":"6","author":"Butler","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.leukres.2015.05.015_bib0220","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/ncb2108","article-title":"Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells","volume":"12","author":"Kobayashi","year":"2010","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.leukres.2015.05.015_bib0225","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.celrep.2013.07.048","article-title":"Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis","volume":"4","author":"Poulos","year":"2013","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm0602-607","article-title":"Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization","volume":"8","author":"Grant","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2003-06-2101","article-title":"Adult human hematopoietic cells provide functional hemangioblast activity","volume":"103","author":"Cogle","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0240","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","article-title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia","volume":"95","author":"Hussong","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2015.05.015_bib0245","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padro","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0250","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1200\/JCO.2005.05.058","article-title":"Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival","volume":"23","author":"Loges","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2015.05.015_bib0255","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bjc.6603966","article-title":"Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia","volume":"97","author":"Lee","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.leukres.2015.05.015_bib0260","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2008-08-173104","article-title":"Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival","volume":"113","author":"Shih","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2015.05.015_bib0265","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/leu.2014.109","article-title":"Functional integration of acute myeloid leukemia into the vascular niche","volume":"28","author":"Cogle","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2015.05.015_bib0270","doi-asserted-by":"crossref","first-page":"pe60823","DOI":"10.1371\/journal.pone.0060823","article-title":"Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism","volume":"8","author":"Pezeshkian","year":"2013","journal-title":"PLOS ONE"},{"issue":"11","key":"10.1016\/j.leukres.2015.05.015_bib0275","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.exphem.2014.08.003","article-title":"Activation of the vascular niche supports leukemic progression and resistance to chemotherapy","volume":"42","author":"Poulos","year":"2014","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.tranon.2014.09.007","article-title":"Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models","volume":"7","author":"Li","year":"2014","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0285","first-page":"37","article-title":"Health care costs among renal cancer patients using pazopanib and sunitinib","volume":"21","author":"Hansen","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0290","first-page":"46","article-title":"Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States","volume":"21","author":"Delea","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"7","key":"10.1016\/j.leukres.2015.05.015_bib0295","first-page":"67","article-title":"[Effect of cytarabine on expression of cell adhesion molecules and on endothelium\u2013leukocyte interaction in vitro]","volume":"78","author":"Chervontseva","year":"2006","journal-title":"Ter. Arkh."},{"issue":"3\u20134","key":"10.1016\/j.leukres.2015.05.015_bib0300","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1139\/Y07-045","article-title":"Vascular endothelium: target or victim of cytostatic therapy?","volume":"85","author":"Romanov","year":"2007","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0305","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.leukres.2007.10.005","article-title":"Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia","volume":"32","author":"Liersch","year":"2008","journal-title":"Leuk. Res."},{"issue":"19","key":"10.1016\/j.leukres.2015.05.015_bib0310","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1073\/pnas.191117498","article-title":"Inhibition of both paracrine and autocrine VEGF\/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias","volume":"98","author":"Dias","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.leukres.2015.05.015_bib0315","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2015.05.015_bib0320","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.leukres.2015.05.015_bib0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2008.07411.x","article-title":"Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators","volume":"144","author":"Hatfield","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2015.05.015_bib0330","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","article-title":"Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia","volume":"16","author":"Padro","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0335","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2015.05.015_bib0340","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.05.015_bib0345","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404632","article-title":"Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity","author":"Zahiragic","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2015.05.015_bib0350","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2015.05.015_bib0355","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.leukres.2009.07.020","article-title":"An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia","volume":"34","author":"Fiedler","year":"2010","journal-title":"Leuk. Res."},{"issue":"21","key":"10.1016\/j.leukres.2015.05.015_bib0360","first-page":"3285-","article-title":"A phase I\/II study combining sunitinib with standard ara-C\/daunorubicin chemotherapy in patients 60 years or older with FLT3 mutated AML","volume":"116","author":"Fiedler","year":"2010","journal-title":"ASH Ann. Meet. Abstr."},{"issue":"6","key":"10.1016\/j.leukres.2015.05.015_bib0365","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood.V99.6.2179","article-title":"Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy","volume":"99","author":"Dias","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2015.05.015_bib0370","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","article-title":"AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model","volume":"121","author":"Wunderlich","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T11:00:53Z","timestamp":1582542053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0145212615001873"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.05.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}